Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Gains from Sales and Divestitures: 2017-2024

Historic Gains from Sales and Divestitures for UroGen Pharma (URGN) over the last 8 years, with Dec 2024 value amounting to $385,065.

  • UroGen Pharma's Gains from Sales and Divestitures rose 31.14% to $385,065 in Q4 2024 from the same period last year, while for Dec 2024 it was $385,065, marking a year-over-year increase of 31.14%. This contributed to the annual value of $385,065 for FY2024, which is 31.14% up from last year.
  • According to the latest figures from FY2024, UroGen Pharma's Gains from Sales and Divestitures is $385,065, which was up 31.14% from $293,626 recorded in FY2023.
  • In the past 5 years, UroGen Pharma's Gains from Sales and Divestitures ranged from a high of $385,065 in FY2024 and a low of $85,954 during FY2020.
  • Moreover, its 3-year median value for Gains from Sales and Divestitures was $374,293 (2022), whereas its average is $350,995.
  • Per our database at Business Quant, UroGen Pharma's Gains from Sales and Divestitures slumped by 53.28% in 2020 and then spiked by 229.42% in 2021.
  • Over the past 5 years, UroGen Pharma's Gains from Sales and Divestitures (Yearly) stood at $85,954 in 2020, then spiked by 229.42% to $283,147 in 2021, then soared by 32.19% to $374,293 in 2022, then declined by 21.55% to $293,626 in 2023, then surged by 31.14% to $385,065 in 2024.